ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere”) – a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported record total revenue for the second quarter of 2008 of $7.61 million, an increase of 9% compared with $6.97 million in the second quarter of 2007. Worldwide revenue of embolics and delivery systems was $7.41 million, up 16% from $6.39 million in the prior year. As previously announced, the gastric product line in Europe is being phased out. Gastric products revenue in Europe was $0.20 million, a decrease of 66% from $0.58 million in Q2 2007.
